-+undefined NaN%
-+undefined NaN%
-+undefined NaN%

RBC Trims Price Target on Pliant Therapeutics to $58 From $60, Maintains Outperform Rating, Speculative Risk

RBC Trims Price Target on Pliant Therapeutics to $58 From $60, Maintains Outperform Rating, Speculative Risk

MT Newswires · 03/10/2023 03:10